JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.65B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.08B |
| 3 |
Microsoft
MSFT
|
+$2.05B |
| 4 |
Vanguard Total International Bond ETF
BNDX
|
+$1.64B |
| 5 |
Micron Technology
MU
|
+$1.39B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMJ
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
|
+$2.4B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.11B |
| 3 |
Progressive
PGR
|
+$1.64B |
| 4 |
Salesforce
CRM
|
+$1.54B |
| 5 |
Adobe
ADBE
|
+$1.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.15% |
| 2 | Technology | 24.03% |
| 3 | Healthcare | 9.24% |
| 4 | Consumer Discretionary | 8.79% |
| 5 | Financials | 8.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6051
MediciNova
MNOV
$80.2M
| $7.74K | ﹤0.01% |
5,376
-28,100
| -84% | -$39.4K |
2016 Q1
33 quarters
|
|
|
QBTS.WS
6052
DELISTED
D-Wave Quantum Inc Warrants
QBTS.WS
| – | – |
0
| – | – |
2023 Q2
4 quarters
|
|
|
ONCT
6053
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $7.63K | ﹤0.01% |
1,004
| – | – |
2020 Q2
16 quarters
|
|
6054
Franklin Investment Grade Corporate ETF
FLCO
$540M
| $7.62K | ﹤0.01% |
361
-730
| -67% | -$15.3K |
2023 Q3
3 quarters
|
|
6055
Neuronetics
STIM
$169M
| $7.58K | ﹤0.01% |
4,212
+4,178
| +12,288% | +$12.1K |
2018 Q3
23 quarters
|
|
6056
First Trust Switzerland AlphaDEX Fund
FSZ
$35.1M
| $7.54K | ﹤0.01% |
116
| – | – |
2023 Q3
3 quarters
|
|
|
MRNS
6057
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $7.53K | ﹤0.01% |
6,439
-27,195
| -81% | -$68K |
2018 Q1
25 quarters
|
|
|
AXIA.PR
6058
DELISTED
AXIA Energia American Depositary Shares Preferred Class B1
AXIA.PR
| $7.36K | ﹤0.01% |
1,310
+1,081
| +472% | +$6.88K |
2023 Q2
4 quarters
|
|
6059
Westwood Holdings Group
WHG
$185M
| $7.28K | ﹤0.01% |
598
+105
| +21% | +$1.31K |
2017 Q4
26 quarters
|
|
6060
Invesco Global Listed Private Equity ETF
PSP
$213M
| $7.27K | ﹤0.01% |
119
-1,741
| -94% | -$112K |
2023 Q2
4 quarters
|
|
6061
Pacer Swan SOS Fund of Funds ETF
PSFF
$611M
| $7.25K | ﹤0.01% |
+261
| New | +$7.09K |
2024 Q2
0 quarters
|
|
6062
First Trust Developed Markets ex-US AlphaDEX Fund
FDT
$1.34B
| $7.23K | ﹤0.01% |
131
+130
| +13,000% | +$7.25K |
2023 Q1
5 quarters
|
|
6063
Matinas BioPharma
MTNB
$2.37M
| $7.22K | ﹤0.01% |
61
| – | – |
2017 Q2
28 quarters
|
|
6064
Hennessy Advisors
HNNA
$82.1M
| $7.18K | ﹤0.01% |
1,009
+1,000
| +11,111% | +$7.09K |
2023 Q3
3 quarters
|
|
6065
WisdomTree International MidCap Dividend Fund
DIM
$157M
| $7.09K | ﹤0.01% |
+117
| New | +$7.29K |
2024 Q2
0 quarters
|
|
|
AIO
6066
Virtus Artificial Intelligence & Technology Opportunities Fund
AIO
$866M
| $6.95K | ﹤0.01% |
320
-28
| -8% | -$560 |
2024 Q1
1 quarter
|
|
|
LFT
6067
Lument Finance Trust
LFT
$27.3M
| $6.83K | ﹤0.01% |
285
+137
| +93% | +$3.34K |
2023 Q3
3 quarters
|
|
6068
State Street SPDR S&P Kensho New Economies Composite ETF
KOMP
$2.64B
| $6.82K | ﹤0.01% |
148
+6
| +4% | +$278 |
2023 Q4
2 quarters
|
|
6069
FT Vest US Equity Enhance & Moderate Buffer ETF March
XMAR
$155M
| $6.78K | ﹤0.01% |
196
| – | – |
2024 Q1
1 quarter
|
|
6070
KORU Medical Systems
KRMD
$139M
| $6.76K | ﹤0.01% |
2,553
-12,090
| -83% | -$27.7K |
2023 Q1
5 quarters
|
|
6071
Tevogen Inc
TVGN
$43.8M
| $6.74K | ﹤0.01% |
186
+185
| +18,500% | +$12.1K |
2024 Q1
1 quarter
|
|
6072
Century Casinos
CNTY
$29.5M
| $6.55K | ﹤0.01% |
2,364
-14,153
| -86% | -$41.1K |
2017 Q4
26 quarters
|
|
|
AFEM
6073
First Trust Exchange-Traded Fund III First Trust Active Factor Emerging Markets ETF
AFEM
$83M
| $6.41K | ﹤0.01% |
97
-8
| -8% | -$509 |
2023 Q1
5 quarters
|
|
|
HDAW
6074
DELISTED
Xtrackers MSCI All World ex US High Dividend Yield Equity ETF
HDAW
| $6.4K | ﹤0.01% |
259
+242
| +1,424% | +$6.08K |
2024 Q1
1 quarter
|
|
6075
LifeVantage
LFVN
$78.6M
| $6.4K | ﹤0.01% |
997
-449
| -31% | -$3.04K |
2023 Q2
4 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2024 Portfolio in Review
As of Q2 2024, JP Morgan Chase held 7,917 positions worth $1.22T, up 3% from $1.18T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q2 2024 filing shows 549 new, 2,506 increased, 3,286 reduced and 578 closed positions. Its largest new stake was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M. The largest sale was JP Morgan Alerian MLP Index ETN 5/24/24, an estimated $2.4B.
By sector, the portfolio is most concentrated in Miscellaneous at 24% of assets, down from 25% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2024 buy was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M.
- JP Morgan Chase added most to Apple in Q2 2024, an estimated $4.65B increase.
- JP Morgan Chase's biggest Q2 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $2.11B.
- JP Morgan Chase fully exited JP Morgan Alerian MLP Index ETN 5/24/24 in Q2 2024, selling an estimated $2.4B.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.22T portfolio in Q2 2024.
- JP Morgan Chase opened 549 new positions and closed 578 in Q2 2024.
- JP Morgan Chase's portfolio value rose 3% quarter-over-quarter to $1.22T.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.